The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
2020 · Pediatric Nephrology · 72 citations
https://doi.org/10.1007/s00467-020-04774-2
B
Brigitte Adams
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
1.2K
Citations
15
h-index
21
i10-index
Brigitte Adams is an academic researcher from Queen Fabiola Children's University Hospital. The author has contributed to research in topics: Complement system in diseases & Renal Diseases and Glomerulopathies & Adenosine and Purinergic Signaling. The author has an h-index of 15, co-authored 41 publications.
ORCID: 0000-0001-9693-2205Papers by this author
worksRavulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
2024 · Kidney Medicine · 19 citations
https://doi.org/10.1016/j.xkme.2024.100855
Clinical outcomes of pediatric kidney replacement therapy after childhood cancer—An ESPN/ERA Registry study
2024 · American Journal of Transplantation · 3 citations
https://doi.org/10.1016/j.ajt.2024.11.002
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat